Huons Co.,Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bundang-gu Seongnam Korea, Republic of (1965)
Status: No NME R&D (1965)

Organization Overview

First Clinical Trial
2013
NCT02492412
First Marketed Drug
2019
levobupivacaine (chirocaine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

HUONS | Huons Co., Ltd. | Huons Co.,Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Fatty Liver (Phase 2)

Hypertension (Phase 1)

Keratoconjunctivitis Sicca (Phase 3)

Liver Diseases (Phase 2)

Muscle Spasticity (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Osteoporosis (Phase 1)

Osteoporosis, Postmenopausal (Phase 1)

Stroke (Phase 1)

Syndrome (Phase 3)

Tooth, Impacted (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 16